Single-Dose Nirsevimab Provides Season-Long RSV Protection for Preterm Infants
Single-dose nirsevimab successfully reduced rates of respiratory syncytial virus-associated lower respiratory infections and hospitalizations in pre-term infants.
Vaccines
Safety, Immunogenicity of Investigational Inactivated Whole-Virus COVID-19 Vaccine
An investigational inactivated whole-virus COVID-19 vaccine has demonstrated safety and immunogenicity, according to an interim analysis.
Underutilization of Influenza Vaccination in Populations at High-Risk for Complications
Influenza vaccinations were found to be underutilized among groups who are considered to be at high risk for complications from infection.
ACIP: Influenza Vaccination Recommendations for 2020-2021
Influenza vaccination should occur by the end of October, if possible.
HHS Authorizes Pharmacists to Administer Vaccines to Children
HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.
Postmarketing Surveillance Demonstrates Remarkable Safety of Vaccines
Vaccines are a key public health strategy that is remarkably safe due to continued postmarketing surveillance programs.
Immunization Schedules: Best Available Evidence for 2020
Review of the Advisory Committee Immunization Practices updates to the pediatric immunization schedule and significant revisions to the adult immunization schedule.
Vaccine Efficacy Required to Prevent or Extinguish COVID-19 Epidemic
Simulation experiments demonstrated that a vaccine efficacy of 80% is required to extinguish the ongoing COVID-19 pandemic without any other additional measures.
Phase 3 Trial of COVID-19 Vaccine Candidate mRNA-1273 Begins
The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.
Flu Vaccine Reduces Cardiovascular Mortality in Adults With Diabetes
The analysis included 241,551 patients monitored for a median of 4 years.
-
Loading...
-
Loading...
Next post in Influenza Information Center
